Company profile: Cyxone
1.1 - Company Overview
Company description
- Provider of biopharmaceutical R&D focused on cyclotide-based drugs for severe autoimmune diseases. Operates via an international expert network across research, development and manufacturing. Pipeline includes Rabeximod, an oral Phase 2 candidate for rheumatoid arthritis targeting inflammatory macrophages, and T20K, an early clinical candidate for multiple sclerosis modulating T cell activity.
Products and services
- Cyclotide Technology Drug Development: Cyclotide-based R&D program that engineers therapeutics for severe autoimmune diseases through an international network spanning research, development, and manufacturing
- Rabeximod: Clinical-stage oral drug candidate for rheumatoid arthritis that targets inflammatory macrophages to mitigate inflammation, currently in Phase 2 clinical development
- T20K: Early-clinical drug candidate for multiple sclerosis that modulates T cell activity to slow disease progression
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cyxone
Lophius Biosciences
HQ: Germany
Website
- Description: Provider of innovative products for the diagnosis of acute infectious and autoimmune diseases, plus custom services in cell-based bioactivity and quality testing for pharmaceutical agents.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lophius Biosciences company profile →
BaroFold
HQ: United States
Website
- Description: Provider of protein therapeutics for immunology indications, focused on discovering, developing and commercializing protein biologics, some incorporating its proprietary PreEMT high-pressure folding technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BaroFold company profile →
Abintus Bio
HQ: United States
Website
- Description: Provider of in vivo immune cell reprogramming solutions, offering programs for highly selective gene expression targeting—using synthetic biology to target specific cell types or states across gene delivery systems—for applications in leukemia, solid tumors, autoimmune, infectious, and genetic diseases, and simultaneous engineering of innate and adaptive immune cells for lymphoma and solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abintus Bio company profile →
Step Pharma
HQ: France
Website
- Description: Provider of CTPS1 inhibition therapies, developing STP938, an orally bioavailable CTPS1 inhibitor in clinical development for treating blood cancers and potentially solid tumors. The approach targets the CTPS1 enzyme to inhibit a key step in nucleotide synthesis to treat various cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Step Pharma company profile →
Triveni Bio
HQ: United States
Website
- Description: Provider of genetically informed functional antibody therapeutics for immunological and inflammatory disorders, supported by a proprietary data platform that leverages public and private datasets to identify therapeutic targets, predict patient subpopulations, and provide disease insights; lead program TRIV-509 targets kallikreins 5 and 7 for atopic dermatitis and other barrier disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Triveni Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cyxone
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cyxone
2.2 - Growth funds investing in similar companies to Cyxone
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cyxone
4.2 - Public trading comparable groups for Cyxone
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →